Annovis Bio, Inc. (ANVS) |
|
12.07 0.73 (6.44%)
|
07-02 16:39 |
|
Open: |
11.54 |
Pre. Close: |
11.34 |
|
High:
|
12.1999 |
Low:
|
11.364 |
|
Volume:
|
50,406 |
Market Cap:
|
99(M) |
|
|
|
|
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.21 - 12.27 |
12.27 - 12.33 |
|
Low:
|
11.23 - 11.29 |
11.29 - 11.35 |
|
Close:
|
11.97 - 12.07 |
12.07 - 12.17 |
|
Technical analysis |
as of: 2022-07-01 4:20:03 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 16.72 One year: 19.53 |
| Support: |
Support1: 11.01 Support2: 8.97 |
| Resistance: |
Resistance1: 14.31 Resistance2: 16.72 |
| Pivot: |
10.98 |
| Moving Average: |
MA(5): 11.86 MA(20): 11.2
MA(100): 11.92  MA(250): 25.41 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 51.9 %D(3): 51.4 |
| RSI: |
RSI(14): 57 |
| 52-week: |
High: 132 Low: 8.39 |
| Average Vol(K): |
3-Month: 41 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANVS ] has closed below upper band by 14.2%. Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 29 Jun 2022
Annovis Bio, Inc.'s (NYSE:ANVS) 25% gain last week benefited both individual investors who own 58% as well as insiders - Simply Wall St
Tue, 28 Jun 2022
Thermal Night Vision System Market 2022 Analysis by Top Manufacturers – FLIR, Speedir NightRide, THEON SENSORS, Opgal – Designer Women - Designer Women
Tue, 14 Jun 2022
Annovis Bio Submits International Patent Application - MyChesCo
Mon, 06 Jun 2022
Will Annovis Bio Inc (ANVS) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Sun, 05 Jun 2022
Atreca (NASDAQ:BCEL) & Annovis Bio (NYSE:ANVS) Critical Analysis - Defense World
Mon, 02 May 2022
LADENBURG THALM/SH SH Initiates Coverage on Annovis Bio (NYSE:ANVS) - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
6 (M) |
|
% Held by Insiders
|
30.9 (%) |
|
% Held by Institutions
|
15.5 (%) |
|
Shares Short
|
180 (K) |
|
Shares Short P.Month
|
221 (K) |
Stock Financials |
|
EPS
|
-2.18 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.15 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-43.8 |
|
Return on Equity (ttm)
|
-74.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-10 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-5.57 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.34 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-10.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
